Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Price:
0.741
USD
-5.63%
Market Cap:
$4.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
|
IL |
|
C
|
Card Factory PLC
OTC:CRFCF
|
UK |
|
S
|
Shandong Hi-Speed Holdings Group Ltd
F:HRI
|
HK |
|
Happiest Minds Technologies Ltd
NSE:HAPPSTMNDS
|
IN |
|
G
|
Gudou Holdings Ltd
HKEX:8308
|
CN |
|
FLEXIROAM Ltd
ASX:FRX
|
MY |
|
Recharge Metals Ltd
ASX:REC
|
AU |
|
Revasum Inc
ASX:RVS
|
US |
|
Triton Minerals Ltd
ASX:TON
|
AU |
|
Shenzhen Colibri Technologies Co Ltd
SZSE:002957
|
CN |
|
Scholar Education Group
HKEX:1769
|
CN |
|
Signal Advance Inc
OTC:SIGL
|
US |
|
Sun&L Co Ltd
KRX:002820
|
KR |
|
Condor Energies Inc
TSX:CDR
|
CA |
|
D
|
Douzone Bizon Co Ltd
KRX:012510
|
KR |
|
Shenzhen Prince New Materials Co Ltd
SZSE:002735
|
CN |
|
Fluence Corporation Ltd
ASX:FLC
|
US |
|
P
|
Pennant Group Inc
NASDAQ:PNTG
|
US |
|
Birchcliff Energy Ltd
TSX:BIR
|
CA |
|
Visagar Polytex Ltd
NSE:VIVIDHA
|
IN |
|
T
|
Toshiba Corp
XBER:TSE1
|
JP |
|
G
|
Global Helium Corp.
CNSX:HECO
|
CA |
|
VerifyMe Inc
NASDAQ:VRME
|
US |
|
9
|
908 Devices Inc.
NASDAQ:MASS
|
US |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of GLMD.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GLMD
Multiples-Based Value
Not Available
Multiples Across Competitors
GLMD Competitors Multiples
Galmed Pharmaceuticals Ltd Competitors
Galmed Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
|
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
|
4.1m USD | 0 | -0.4 | 0.8 | 0.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
367.6B USD | 6 | 87.2 | 14.5 | 20.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.2B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.5B USD | 5.9 | 20.3 | 12.7 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 9.3 | 28.2 | 21.2 | 22.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.5 | 13 | 14.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 11.8 | 37.9 | 40.9 | 41.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 2.9 | 32.3 | 10.9 | 13.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
